Atovaquone

證據等級: L5

預測適應症: 0 個

Atovaquone (DB01117): Drug Repurposing Evaluation — Critical Data Gaps Identified

One-Sentence Summary

Atovaquone (DrugBank ID: DB01117) has been submitted for drug repurposing evaluation via the TxGNN prediction pipeline. Unfortunately, this Evidence Pack contains critical data gaps — including absent predicted indications, missing mechanism of action data, and no UK regulatory licensing records — that prevent a substantive repurposing assessment at this stage. No evidence level can be assigned until the pipeline is re-run with complete input data.

Quick Overview

Item	Content
Original Indication	No data available
Predicted New Indication	No TxGNN predictions generated
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
UK Market Status	Not marketed (per current data)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Safety Considerations

No safety data was returned for this candidate. Please refer to the current SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk).

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Atovaquone is incomplete in several blocking respects: the TxGNN model returned no predicted repurposing indications, and drug-level inputs (approved indications, mechanism of action, MHRA licensing) are all absent. No repurposing evaluation can be conducted without these foundational inputs.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline — confirm that Atovaquone’s DrugBank ID (DB01117) is correctly mapped and that the knowledge graph contains sufficient edges for prediction; an empty predicted_indications array suggests a mapping or pipeline failure rather than a genuine null result
Retrieve MOA from DrugBank API — query https://go.drugbank.com/drugs/DB01117 to obtain mechanism of action, drug categories, and pharmacodynamics; this is required for mechanistic plausibility analysis
Verify MHRA marketing authorisation status — Atovaquone-containing products (e.g. suspension formulations and combination products) may be authorised in Great Britain; cross-check against the MHRA product licence register and the Electronic Medicines Compendium (EMC) before confirming “not marketed” status
Obtain SmPC safety data — download and parse the relevant SmPC(s) for approved warnings, contraindications, and drug interaction information to populate the safety section
Confirm drug classification — determine whether Atovaquone meets criteria for the Cytotoxicity section (antiparasitic/antiprotozoal agents are typically excluded, but confirmation of DrugBank categories is needed)

Note: This report reflects only the data provided in the submitted Evidence Pack (version v4, data cutoff 2026-04-04). The two blocking data gaps logged in the Evidence Pack meta — DG001 (MHRA SmPC warnings/contraindications) and DG002 (mechanism of action) — must be resolved before this candidate can be re-evaluated. Please resubmit with a complete Evidence Pack once the remediation steps above have been completed.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.